Gilead sets aside $200M for potential settlement over HIV drug speaker program
Gilead set aside approximately $200 million for a potential resolution of an eight-year case surrounding its promotional speaker program for HIV drugs.
Gilead set aside approximately $200 million for a potential resolution of an eight-year case surrounding its promotional speaker program for HIV drugs.
